

	NAME 藍先元 Lane, Hsien-Yuan		POSITION TITLE Director Professor	
	EDUCATION/TRAINING			
	INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Taipei Medical College, Taipei	M.D.	1987	Medicine	
Board Certified in Psychiatry		1992		
National Defense Medical College, Taipei	Ph.D.	2000	Life Sciences	

CURRENT POSITIONS

Distinguished Professor & Director, Graduate Institute of Biomedical Sciences,
 China Medical University Medical College, Taichung, Taiwan
 Director, Department of Psychiatry,
 Director, Brain Diseases Research Center (BDRC),
 Director, Addiction Research Center,
 China Medical University and Hospital, Taichung, Taiwan
 PI, Taiwan Clinical Trial Consortium for Mental Disorders
 President, Taiwanese Society of Schizophrenia Research
 Chair, Education Committee, Taiwanese Society of Psychiatry
 Fellow, The International College of Neuropsychopharmacology (CINP)

RESEARCH INTEREST

1. Neuropsychopharmacology
2. Cognitive neuroscience
3. Precision medicine

HONORS

1996,1997,1998 Young Investigator Award, National Science Council, Taiwan
 1999, 2000 Senior Investigator Award, National Science Council, Taiwan
 2005 A-class Research Award, National Science Council, Taiwan (for 3 years)
 2005 Distinguished Investigators Award, China Medical University, Taiwan
 2006 Y.Z. Hsu Scientific Paper Award, Biotechnology Category, Taiwan
 2000, 2003, 2004, 2005, 2006, 2007
 Schizophrenia Research Award, Society of Psychiatry, Taiwan (since 2008, this award is limited to a maximum of 3 times)
 2007 Distinguished Research Paper Award, National Cheng Kung University Medical College, Taiwan
 2007 Distinguished Investigators Award, China Medical University, Taiwan (for 3 years)
 2008 Distinguished Research Paper Award, China Medical University, Taiwan
 2009, 2010, 2011-2012 Distinguished Research Awards, China Medical University, Taiwan
 2009, 2011 Research Award, Taiwanese Society of Biological Psychiatry
 2009 Research Award on 3-Consecutive NHRI Projects, National Health Research Institute
 2012-2014 Laureat Research Award, China Medical University, Taiwan
 2011- Fellow, International College of Neuropsychopharmacology
 2013 The 10th National Innovation Award, Taiwan
 2014 The 24th Wang-Ming-Ning Award
 2014 Ministry of Science and Technology Outstanding Research Award
 2016 The International of College of Neuropsychopharmacology CINP CNS Drug Innovation Award

EDITORIAL BOARD (since 2009)

2010-present, ISRN Pharmacology

2011-present, World Journal of Psychiatry
2011-present, Open Journal of Psychiatry
2012-present, World Journal of Neurology
2012-present, World Journal of Pharmacology
2012-present, International Journal of Biology and Biological Sciences
2012-present, International Journal of Bipolar Disorders
2013-present, Journal of Medicine and Medical Research
2014-2015 The Scientific World Journal (guest editor) (SCI)
2014-present, Neurotransmitter
2014-present, Journal of Addiction and Neuropharmacology
2014-present, Journal of Schizophrenia Research
2014-present, International Scholarly Research Notices
2014-present, Journal of Clinical and Experimental Genetics
2015-present, Gerontology & Geriatrics: Research
2015-present, Archives of Depression and Anxiety
2015-present, Austin Addiction Sciences
2015-present, Journal of Psychiatry, Depression & Anxiety
2016-present, Asia Pacific Clinical and Translational Nervous System Diseases
2016-present, The Scientific Pages of Alzheimer's Disease & Dementia
2016-present, JSM Schizophrenia
2016-present, Austin Child & Adolescent Psychiatry
2016-present, Journal of Psychiatry & Mental Disorders
2016-present, Journal of Biotechnology
2016-present, Biomarker Research
2016-present, Scientific Reports

REVIEWER (since 2009)

2009, BMJ Case Reports
2009, Journal of Formosan Medical Association (3 papers)
2009, Journal of Clinical Psychopharmacology (2 papers)
2009, Journal of Psychiatric Research
2009, Biological Psychiatry (2 papers)
2009, Recent Patents on CNS Drug Discovery
2009, World Journal of Biological Psychiatry
2009, The Pharmacogenomics Journal
2009, Journal of Translational Medicine
2009, Journal of Clinical Psychiatry (2 papers)
2009, Schizophrenia Bulletin
2010, Biological Psychiatry
2010, Journal of Clinical Psychopharmacology (7 papers)
2010, Journal of Formosan Medical Association
2010, Journal of Psychopharmacology
2010, Current Pharmaceutical Biotechnology
2010, Schizophrenia Research
2010, International Journal of Neuropsychopharmacology
2010, BMC Psychiatry
2010, Neuropsychobiology
2010, Journal of Clinical Psychiatry (4 papers)
2011, Journal of Clinical Psychopharmacology (4 papers)
2011, Journal of Clinical Psychiatry (2 papers)
2011, CNS Drugs
2011, Acta Neuropsychiatrica
2011, Journal of Medicine and Medical Sciences
2011, Pharmacogenomics
2011, Comprehensive Psychiatry
2011, The Open Psychiatry Journal (2 papers)
2011, Translational Psychiatry
2011, Journal of Psychiatry and Neuroscience
2011, Comprehensive Psychiatry

2011, Molecular Diagnosis & Therapy
2011, Schizophrenia Research (2 papers)
2011, Schizophrenia Bulletin
2011, ISRN Pharmacology
2011, Biological Psychiatry
2012, Journal of Public Health and Epidemiology
2012, ISRN Pharmacology (2)
2012, Psychiatric Service
2012, Psychiatric Research
2012, Mitochondrion
2012, DNA and Cell Biology
2012, The Open Psychiatry Journal
2012, Journal of Psychopharmacology
2012, Expert Opinion On Pharmacotherapy
2012, Expert Review of Neurotherapeutics
2012, Comprehensive Psychiatry
2012, BMC Psychiatry
2012, Pharmacogenomics
2012, Expert Review of Clinical Pharmacology
2012, Medical Hypotheses
2012, Journal of Clinical Psychopharmacology
2012, Journal of Clinical Psychiatry
2012, Biological Psychiatry
2013, Psychiatry Research (2)
2013, Journal of Biomedical Science
2013, Journal of Psychopharmacology
2013, Pharmacogenomics (3)
2013, Pharmacopsychiatry
2013, Journal of Clinical Psychopharmacology
2013, PLoS One (2)
2013, General Hospital Psychiatry
2013, Schizophrenia Research (2)
2013, International Journal of Neuropsychopharmacology (2)
2013, Biological Psychiatry
2013, Journal of Psychiatry and Neuroscience
2014, Translational Psychiatry
2014, Pharmacogenomics (5)
2014, PLoS One
2014, Journal of Comparative Effectiveness Research
2014, The Kaohsiung Journal of Medical Sciences (3)
2014, Chinese Journal of Physiology
2014, Scientific Reports
2014, Metabolic Brain Disease (2)
2014, Journal of Psychopharmacology (2)
2014, Journal of Affective Disorders
2014, European Neuropsychopharmacology
2014, American Journal of Alzheimer's Disease and Other Dementias
2014, Scientific Reports (2)
2014, Journal of Clinical Psychiatry
2014, The Lancet Psychiatry
2014, Biological Psychiatry
2014, Expert Review of Neurotherapeutics
2015, Annals of General Psychiatry
2015, Pharmacogenomics
2015, The Kaohsiung Journal of Medical Sciences
2015, Expert Review of Neurotherapeutics
2015, Journal of Depression and Therapy
2015, BMC Psychiatry
2015, Journal of Psychopharmacology (3)
2015, Pharmacopsychiatry

2015, Journal of Comparative Effectiveness Research
2015, Psychiatry Research (2)
2015, Journal of Affective Disorders
2015, Journal of Clinical Psychopharmacology (2)
2015, Journal of Clinical Psychiatry (2)
2015, Scientific Reports (3)
2015, Acta Psychiatrica Scandinavica
2016, Expert Opinion On Investigational Drugs
2016, Journal of Psychopharmacology (3)
2016, Pharmacogenomics
2016, Psychiatry Research (2)
2016, Psychiatry Research: Neuroimaging
2016, Acta Neuropsychiatrica
2016, International Journal of Molecular Sciences
2016, World Journal of Psychiatry (2)
2016, Journal of Affective Disorders
2016, Neural Plasticity
2016, Scientific Reports (8)
2016, Schizophrenia Research
2016, Biological Psychiatry

Invited Session Leader

2001, Session leader for the “Acute Management of Schizophrenia” at the third Asia Pacific Psychopharmacology Workshop, Phuket, Thailand, June 1-2, 2001,
2011, Chair for “New Research” at The 2nd Congress of Asian College of Neuropsychopharmacology, Seoul, Korea, September 23-24, 2011.
2013, Chair for “The dark side of antipsychotics” at The 3rd Asian Congress on Schizophrenia Research, Bali, Indonesia, February 14-16, 2013.
2013, Chair for “Novel NMDA modulators for depression, OCD, and dementia: Treatment and imaging” at the 11th World Congress of Biological Psychiatry, Kyoto, Japan, June 23-27, 2013.
2015, Chair for invited speech “Treatment Options in Schizophrenia: Bridging Unmet Needs and New Findings” in the WPA International Congress 2015 (WPAIC 2015), Taipei, Taiwan, November 18 – 22, 2015.

Invited Speaker

2007, Invited speaker for the symposium “Current status and future perspectives on clinical trials of schizophrenia in East Asian countries” at the World Psychiatric Association Regional Meeting in Seoul, Korea, April 18-21, 2007.
2008, Invited speaker for the symposium “Time course of the antipsychotic effect” for the inaugural meeting of the Schizophrenia International Research Society in Venice, June 21-25, 2008.
2008, Invited speaker for the symposium “Fostering collaboration between Western and Eastern schizophrenia researchers” at the Schizophrenia International Research Society Workshop in Hong Kong, October 25-26, 2008
2009, Invited speaker for the workshop of “Psychopharmacology” at the 1st Asian Workshop on Schizophrenia Research in Osaka, Japan, January 31-February 1, 2009
2009, Invited speaker for the 1st Asian College of Neuropsychopharmacology (AsCNP) meeting in Kyoto, Japan, November 12-14, 2009
2011, Invited speaker for the 2nd Asian Congress on Schizophrenia Research (ACoSR), in Seoul, Korea, February 11-12, 2011.
2011, Oral presentation in the 13th International Congress of IFPE: Social cognition in schizophrenia patients treated with typical vs. atypical antipsychotic agents, March 30-April 2, 2011
2012, Symposium in the 28th CINP World Congress of Neuropsychopharmacology Stockholm, Sweden, June 3-7, 2012.
2013, Symposium of “Modulation of glycine transporter inhibitor and D-amino acid oxidase inhibitor for schizophrenia and other mental disorders” in the 3rd Asian Congress on Schizophrenia Research, Bali, Indonesia, February 14-16, 2013.
2013, Symposium of “Novel NMDA mechanisms and modulators for schizophrenia” in the 11th World Congress of Biological Psychiatry, Kyoto, Japan, June 23-27, 2013.
2014, Symposium of “Novel treatment and diagnostic method for schizophrenia based upon D-amino acid oxidase (DAAO) and DAAO activator (G72)” in the 16th World Congress of Psychiatry, Madrid, Spain, September 14-18, 2014.
2015, Symposium of “D-amino acids and D-amino acid oxidase (DAAO) based modulation of NMDAR neurotransmission: Diagnostic and therapeutic implications” in the 12th World Congress of World Federation of Societies of Biological Psychiatry (WFSBP), Athens, Greece, June 14 – 18, 2015.
2015, Invited speaker “Novel NMDA modulation for Alzheimer's disease” in the 1st Annual World Congress Dementia-2015,

Kaohsiung, Taiwan, November 26-28, 2015.

2015, Symposium of “New Therapeutics and Biomarkers for Cognitive Impairments” in the WPA International Congress 2015 (WPAIC 2015), Taipei, Taiwan, November 18 – 22, 2015.

2015, Invited speaker “Modulation of NMDA receptor-mediated neurotransmission: clinical implication for mental disorders” in the WPA International Congress 2015 (WPAIC 2015), Taipei, Taiwan, November 18 – 22, 2015.

2016, Symposium of “Breaking the ground – Evidence for novel classes of anti-depression agents beyond Ketamine” in the 30th CINP World Congress of Neuropsychopharmacology, Seoul, Republic of Korea, July 3-5, 2016

PEER-REVIEWED PUBLICATIONS (SINCE 2009)

1. Chen CM, Hou YT, Liu JY, Wu YR, Lin CH, Fung HC, Hsu WC, Hsu Y, Lee SH, Hsieh-Li HM, Su MT, Chen ST, **Lane HY**, Lee-Chen GJ (2009): PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. *Am J Med Genet B Neuropsychiatr Genet.* 150B:124-129 (sci)
2. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, **Lane HY*** (2009): Lack of association between AKT1 variances vs. clinical manifestations and social function in patients with schizophrenia. *Journal of Psychopharmacology* 23:937-943 [***corresponding author**]
3. Ma WF, Yen JW, Chen WC, Chang HJ, Huang XY, **Lane HY*** (2009). The roles of state and trait anxiety in physical activity participation for Taiwanese adults with anxiety disorders. *Journal of Formosa Medical Association.* 108(6), 481-492. [***corresponding authors**]
4. Chang JP, Tsai CH, Wu PL, **Lane HY**, Su KP (2009): Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression. *Prog Neuropsychopharmacol Biol Psychiatry.* 33: 739-740.
5. Chang YC, **Lane HY** (2009): Reply to Comments on “Optimizing early prediction for antipsychotic response in schizophrenia. *Journal of Clinical Psychopharmacology* 29: 391.
6. Huang YJ, **Lane HY**, Liao CH, Huang CC (2009): Recurrent pancreatitis without eosinophilia on clozapine rechallenge. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 33: 1561-1562.
7. **Lane HY**, Lin C-H, Huang CL, Chang YC, Liao CH, Tsai GE (2010): A Randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. *International Journal of Neuropsychopharmacology* 13:451-460 (sci)
8. Lo CH, Tsai G, Liao CH, Wang MY, Chang JPC, Tsuang HC, **Lane HY*** (2010): Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. *Biological Psychology* 83:79-83 [***corresponding author**]
9. **Lane HY**, Tsai GE, Lin E (2010): The serotonin transporter gene-linked polymorphic region (5-HTTLPR) in recent research on pharmacogenomics and disease susceptibility. *Personalized Medicine* 7: 139-141.
10. Lin CH, Chen MC, Chou LS, Lin CH, Chen CC, **Lane HY*** (2010): Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. *Psychiatric Research* 180: 74-79 [***corresponding author**]
11. Ma WF, Tsai GE, Chang JP, **Lane HY*** (2010): Reliability and validity of three Chinese version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test. *J Clin Nursing* 19:2656-2658 [***corresponding author**]
12. Ma WF, Wu PL, Yang SJ, Cheng KF, Chiu HT, **Lane HY** (2010): Sensitivity and specificity of the Chinese version of the Schizotypal Personality Questionnaire-Brief for identifying undergraduate students susceptible to psychosis. *International Journal of Nursing Studies* 47:1535-1544.
13. Lin CH, Hsu CW, Lin CH, **Lane HY*** (2010): Mirtazapine-associated hair loss. *The Journal of Clinical Psychiatry* 71:1400-1401 [***corresponding author**]
14. Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, **Lane HY*** (2010): A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. *Journal of Clinical Psychopharmacology* 30: 518-525 [***corresponding author**]
15. Tseng YL, Chiang ML, Huang TF, Su KP, **Lane HY**, Lai YC (2010): A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. *Thrombosis Research* 126:517-523.
16. Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, **Lane HY**, Sung FC (2011): Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population based study. *Schizophrenia Research* 126:110-116.
17. Lin CH, **Lane HY**, Chen CC, Juo SHH, Yen CF (2011): Early prediction of fluoxetine response for Han-Chinese inpatients with major depressive disorder. *Journal of Clinical Psychopharmacology* 31: 187-193.
18. Lee MTM, Chen CH, Lee CS, Chen CC, Chong MY, Ouyang WC, Chiu NY, Chuo LJ, Chen CY, Tan HKL, **Lane HY**, Chang TJ, Lin CH, Jou SH, Hou YM, Feng J, Lai TJ, Tung CL, Chen TJ, Chang CJ, Lung FW, Chen CK, Shiah IS, Liu CY, Teng PR, Chen KH, Shen LJ, Cheng CS, Chang TP, Li CF, Chou CH, Chen CY, Wang KHT, Fann CSJ, Wu JY, Chen YT, Cheng ATA (2011): Genome-wide Association study of bipolar I disorder in the Han Chinese population. *Molecular Psychiatry* 16:548-556
19. Wu PL, Tang HS, **Lane HY**, Tsai CA, Tsai GE (2011): Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. *Journal of Clinical Psychopharmacology* 31:369-374
20. Lin CH, **Lane HY*** (2011): Reply to comments by Dr. Suzuki on "A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia". *J Clin Psychopharmacol* 31:399-400 [***corresponding author**].
21. Chen PK, Fuh JL, **Lane HY**, Chiu PY, Tien HC, Wang SJ (2011): Morning headache in habitual snorers: Frequency, characteristics, predictors and impacts. *Cephalalgia.* 31:829-836.
22. Lin CH, **Lane HY**, Chen CC, Juo SH, Yen CF (2011): Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. *Psychiatry Clin Neurosci.* 65:510-517.

23. Liao CH, Chang CS, Chang SN, **Lane HY**, Lyu SY, Morisky DE, Sung FC (2011): The risk of temporomandibular disorder in patients with depression: a population-based cohort study. *Community Dent Oral Epidemiol.* 39:525-531.
24. Lin CH, **Lane HY**, Chen CC, Juo SHH, Yen CF (2011): Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. *The Clinical Journal of Pain* 27:805-810.
25. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, **Lane HY*** (2011): Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. *Pharmacogenomics* 12:1525-1533 [***corresponding author**]
26. Su CH, Liu LC, Hsieh YH, Wang HC, Tsai CW, Chang WS, Ho CY, Wu CI, Lin CH, **Lane HY**, Bau DT (2011): Association of Alpha B-Crystallin (CRYAB) Genotypes with breast cancer susceptibility in Taiwan. *Cancer Genomics Proteomics.* 8:251-254.
27. Liu LC, Su CH, Wang HC, Tsai CW, Chang WS, Ho CY, Wu CI, Li FJ, Lin CH, **Lane HY**, Bau DT (2011): Significant Association of Caveolin-1 (CAV1) Genotypes with breast cancer in Taiwan. *Anticancer Research.* 31:3511-3515.
28. Chen HY, Chang YC, **Lane HY** (2011): Correlation in retinal nerve fiber layer thickness between two OCT units. *Optometry and Vision Science* 88:1326-1332.
29. Ten P, **Lane HY*** (2011): Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. *The Journal of Neuropsychiatry and Clinical Neurosciences* 23(4):E16-7. [***corresponding author**]
30. Lin CH, **Lane HY**, Tsai GE (2012): Glutamate signaling in the pathophysiology and therapy of schizophrenia. *Pharmacology, Biochemistry and Behavior* 100:665-677.
31. Yeh CC, Liao CC, Muo CH, Chang SN, Hsieh CH, Chen FN, **Lane HY**, Sung FC (2012): Mental disorder as a risk factor for dog bites and post-bite cellulitis. *Injury* 43:1903-1907.
32. Chang KC, Huang CL, Liang HY, Chang SS, Wang YC, Liang WM, **Lane HY**, Chen CH, Stephen Huang SK (2012): Differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. *Journal of Cardiovascular Electrophysiology* 23:527-533.
33. **Lane HY**, Tsai G, Lin E (2012): Rapid antidepressant effects of ketamine on circadian gene expression. *Personalized Medicine* 9(1): 15-16.
34. **Lane HY**, Tsai G, Lin E (2012): Assessing gene-gene interactions in pharmacogenomics. *Molecular Diagnosis & Therapy* Feb 1;16(1):15-27. doi: 10.2165/11597270-000000000-00000
35. Lin CH, Huang KH, Chang YC, Huang YC, Hsu WC, Lin CY, Chou FHC, Tsi GE, **Lane HY*** (2012): Clozapine protects bone mineral density in female patients with schizophrenia. *International Journal of Neuropsychopharmacology* 15:897-906 [***corresponding author**]
36. Huang YJ, Lin CH, **Lane HY**, Tsai G (2012): NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease. *Current Neuropharmacology* 10(3):272-285.
37. Wu PL, **Lane HY**, Tang HS, Tsai GE (2012). Glutamate theory in developing novel pharmacotherapies for obsessive compulsive disorder: Focusing on N-methyl-D-aspartate signaling. *BioMedicine*, 2 (2): 75-79.
38. Chang HJ, Lane HY, Tsai GE (2012): The hypothesis of NMDA receptor hypofunction for schizophrenia. *Taiwanese Journal of Psychiatry* 26:147-161.
39. Lai CH, **Lane HY**, Tsai G (2012): Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naive patient with major depression. *Biological Psychiatry* 71(4):e9-e10.
40. Lin MT, Huang KH, Huang CL, Huang YJ, Tsai G, **Lane HY*** (2012): *MET* and *AKT* genetic influence on facial emotion perception. *PLoS ONE* 7(4): e36143. doi:10.1371/journal.pone.0036143 [***corresponding author**]
41. Lin CH, Chou LS, Lin CH, Hsu, CY, Chen CC, **Lane HY*** (2012): Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia. *Journal of Clinical Psychopharmacology* Dec;32(6):773-7. doi: 10.1097/JCP.0b013e318270dfca. [***corresponding author**]
42. Ma WF, Liu YC, Chen YF, **Lane HY**, Lai TJ, Huang LC (2012): Evaluation of psychometric properties of the Chinese mandarin version State-Trait Anxiety Inventory Y form in Taiwanese outpatients with anxiety disorders. *Journal of Psychiatric and Mental Health Nursing* 20(6):499-507
43. Tsuang HC, Chen WJ, Lin SH, Chen TY, Chang TL, Huang KH, **Lane HY*** (2013): Impaired impulse control is associated with a 5-HT2A receptor polymorphism in schizophrenia. *Psychiatry Research* 208(2): 105-110 [***corresponding author**]
44. Lin CY, **Lane HY**, Chen TT, Wu YH, Wu CY, Wu VY (2013): Inverse association between cancer risks and age in schizophrenic patients: A 12-year nationwide cohort study. *Cancer Science* 104(3):383-90.
45. Chen HY, Chang YC, Chen WC, **Lane HY** (2013): Association between plasma endothelin-1 and severity of different types of glaucoma. *Journal of Glaucoma* 22(2):117-22. doi: 10.1097/IJG.0b013e31822e8c65.
46. Lin CH, Huang CL, Chang YC, Chen PW, Lin CY, Tsai GE, **Lane HY*** (2013): Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. *Schizophrenia Research* 146(1-3):231-7 [***corresponding author**]
47. Lin CH, Chen CC, Wang FC, **Lane HY*** (2013): Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission. *Psychiatry and Clinical Neurosciences* 67:265-272. [***corresponding author**]
48. Lin CH, Chen, MC. Lee WK, Chen CC, Huang CH, **Lane HY***(2013): ECT improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients. *Neuropsychobiology.* 68:110-115. [***corresponding author**]
49. Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, **Lane HY*** (2013): Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. *International Clinical Psychopharmacology* 28:267-274 [***corresponding author**]
50. Lin CH, Tseng YL, Huang CL, Chang YC, Tsai GE, **Lane HY*** (2013): Synergistic effects of COMT and TPH2 on social cognition. *Psychiatry: Interpersonal and Biological Processes* 76(3):273-294. [***corresponding author**]
51. Hung CC, Chiou MH, Teng UN, Hsieh YW, Huang CL, **Lane HY*** (2013): Functional impact of ABCB1 variants on

- interaction between P-glycoprotein and methadone. *PLoS One* 8(3):e59419. doi: 10.1371/journal.pone.0059419. Epub 2013 Mar 19. [***corresponding author**]
52. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, **Lane HY***, Tsai G. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. *Biological Psychiatry* 2013 Nov 15;74(10):734-41. doi: 10.1016/j.biopsych.2013.02.020. Epub 2013 Apr 3. [***corresponding author**]
 53. Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, **Lane HY*** (2013): Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. *Molecular Psychiatry* 2013 Jul 16. doi: 10.1038/mp.2013.80. [Epub ahead of print] [***corresponding author**]
 54. **Lane HY**, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE (2013): A randomized, double-blind, placebo-controlled add-on treatment of benzoate, a D-amino acid oxidase inhibitor, for schizophrenia. *JAMA Psychiatry* 70(12) 1267-1275.
 55. Chang SL, Hsieh CH, Chen YJ, Wang CM, Shih CS, Huang PW, Mir A, **Lane HY**, Tsai GE, Chang HT. The C-Terminal Region of G72 Increases d-Amino Acid Oxidase Activity. *Int J Mol Sci.* 2013 Dec 20;15(1):29-43. doi: 10.3390/ijms15010029.
 56. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Lee YC, Chuo LJ, Chiu NY, Tsang HY, Chang TJ, Lung FW, Chiu CH, Chang CH, Chen YS, Hou YM, Chen CC, Lai TJ, Tung CL, Chen CY, **Lane HY**, Su TP, Feng J, Lin JJ, Chang CJ, Teng PR, Liu CY, Chen CK, Liu IC, Chen JJ, Lu T, Fan CC, Wu CK, Li CF, Wang KH, Wu LS, Peng HL, Chang CP, Lu LS, Chen YT, Cheng AT; Taiwan Bipolar Consortium. Variant GADL1 and response to lithium therapy in bipolar I disorder. *N Engl J Med.* 2014;370(2):119-28.
 57. Chang JP, **Lane HY**, Tsai GE. Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation. *Curr Pharm Des.* 2014 Jan 9. [Epub ahead of print]
 58. Lin CH, Huang YJ, **Lane HY**, Tsai GE. NMDA Neurotransmission dysfunction in mild cognitive impairment and Alzheimer's Disease. *Curr Pharm Des.* 2014 Jan 9. [Epub ahead of print]
 59. Lin CY, Tsai GE, **Lane HY***. Assessing and treating cognitive impairments in schizophrenia: current and future. *Curr Pharm Des.* 2014 Jan 10. [Epub ahead of print] [***corresponding author**]
 60. Chang HJ, **Lane HY***, Tsai GE. NMDA Pathology and treatment of schizophrenia. *Curr Pharm Des.* 2014 Jan 10. [Epub ahead of print] [***corresponding author**]
 61. Tsai CH, Huang HC, Liu BL, Li CI, Lu MK, Chen X, Tsai MC, Yang YW, **Lane HY***. Sarcosine (N-methylglycine), a glycine transporter I inhibitor, ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia: a randomized placebo-controlled trial. *Psychiatry and Clinical Neurosciences* 2014 <http://onlinelibrary.wiley.com/doi/10.1111/pcn.12175/abstract> [***corresponding author**]
 62. Lin CY, Tsai G, Wang HS, Wu YH, Chiou CC, Wu VY, **Lane HY***. Effectiveness of Aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. *J Clin Psychiatry* (Accepted). [***corresponding author**]
 63. Lin E, **Lane HY***. Research highlights: genetic association of the NDUFS1 gene with antipsychotic-induced weight gain in schizophrenia. *Pharmacogenomics.* 2014;15(4): 415-7. [***corresponding author**]
 64. Lin CH, Chen PK, Chou LJ, Chang YC, Chen YS, Tsai GE, **Lane HY*** (2014). Benzoate, a D-amino acid oxidase inhibitor, for treatment of early-phase Alzheimer's disease: a randomized, double-blind, placebo-controlled trial. *Biol Psychiatry* 75(9):678-85 [***corresponding author**]
 65. Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, **Lane HY*** (2014): Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. *Molecular Psychiatry* 19(6):636-7. doi: 10.1038/mp.2013.80. Epub 2013 Jul 16. [***corresponding author**]
 66. Chen YT, Huang MW, Hung IC, **Lane HY**, Hou CJ (2014): Right and left amygdalae activation in patients with major depression receiving antidepressant treatment, as revealed by fMRI. *Behav Brain Funct.* Oct 8;10(1):36. doi: 10.1186/1744-9081-10-36
 67. Lin E, **Lane HY*** (2014): Highlights from the latest articles in pharmacogenomics of antipsychotics. *Pharmacogenomics.* 15(4): 415-7. [***corresponding author**]
 68. Ma WF, **Lane HY**, Chiang LC, Wu PL, Yang SJ, Tsai GE (2015): Assessing the construct validity of the Chinese-version Schizotypal Personality Questionnaire-Brief on male and female undergraduate students. *J Nurs Res.* 2015 Jun;23(2):162-6.
 69. Hsu WY, **Lane HY**, Lin CL, Kao CH (2015): A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. *Schizophr Res.* 2015 Mar;162(1-3):248-52.
 70. Lin CH, Lin CY, Huang TL, Wang HS, Chang YC, **Lane HY*** (2015): Sex-specific factors for bone density in patients with schizophrenia. *Int Clin Psychopharmacol.* 2015 Mar;30(2):96-102. [***corresponding author**]
 71. Wu YS, **Lane HY**, Lin CH (2015): Donepezil improved cognitive deficits in a patient with Neurosyphilis. *Clin Neuropharmacol.* 2015 Jul-Aug;38(4):156-7.
 72. Chen VC, Liao YT, Lai TJ, **Lane HY**, Shao WC, Dewey M, Lee CT, Lu ML. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study. *Schizophr Res.* 2015 Oct 15. pii: S0920-9964(15)30005-0. doi: 10.1016/j.schres.2015.10.005. [Epub ahead of print]
 73. Lin E, **Lane HY*** (2015): Pharmacogenomics studies of antidepressants. *Pharmacogenomics.* Apr;16(5):555-66. [***corresponding author**]
 74. Lin CY, Liang SY, Change YC, Ting SY, Kao CL, Wu YH, Tsai GE, **Lane HY***(2015): Adjunctive sarcosine plus benzoate improved cognitive and global function in chronic schizophrenia patients with constant clinical symptoms: a randomized, double-blind, placebo-controlled trial. *World J Biol Psychiatry* Dec 22:1-12. [Epub ahead of print] [***corresponding author**]
 75. Lu YY, Lin CH, **Lane HY*** (2016): Mania following ketamine abuse. *Neuropsychiatric Disease and Treatment.* Jan 27;12:237-9. doi: 10.2147/NDT.S97696. eCollection 2016
 76. Lin CH, Yang WC, Chen MC, **Lane HY*** (2016): Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy. *European Neuropsychopharmacology* Feb;26(2):225-33 [***corresponding author**]

77. Lin PC, **Lane HY**, Lin CH (2016): Spontaneous remission of ketamine withdrawal-related depression. *Clin Neuropharmacol.* 39(1):51-2. doi: 10.1097/WNF.0000000000000121.
78. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, Hert MD, Olfson M, Kahl KG, Martin A, Jeff, **Lane HY**, Sung FC, Liao CH, Arango C, Correll CU (2016): Type 2 Diabetes in Youth Exposed to Antipsychotics: A Systematic Review, Meta-analysis and Exploratory Metaregression Analysis. *JAMA Psychiatry* Jan 20. doi: 10.1001/jamapsychiatry.2015.2923. [Epub ahead of print]
79. Wu JYW, Ko HC, **Lane HY** (2016): Personality disorders in female and male college students with internet addiction. *Journal of Nervous and Mental Disease.* Jan 5. [Epub ahead of print]
80. Lin CH, Lin PP, Lin CY, Lin CH, Huang CH, Huang YJ, **Lane HY*** (2016): Decreased mRNA expression for the two subunits of system xc-, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. *J Psychiatr Res.* 22;72:58-63. doi: 10.1016/j.jpsychires.2015.10.007. [*corresponding author]
81. Mao WC, Chen LF*, Chi CH, Lin CH, Kao YC, Hsu WY, Lane HY, Hsieh JC* (2016): Traditional Chinese version of the Mayer Salovey Caruso Emotional Intelligence Test (MSCEIT-TC): its validation and application to schizophrenic individuals. **Psychiatry Research** Decision on your Submission PSY-D-15-00417R2

Current Grants:

National Health Research Institutes (NHRI):

1. Collaboration translational research on addiction (NHRI-104A1-PDCO-1415161)(2015-2016)

National Research Program for Biopharmaceuticals (NRPB)/ Ministry of Science and Technology (MOST)

1. D-amino acid oxidase inhibitor for treatment of behavioral and psychological symptoms in dementia (MOST 105-2325-B-039-005 -) (2016/05/01-2017/04/30)
2. Taiwan Clinical Trial Consortium for mental disorders (MOST 105-2325-B-039-002 -)(2016/05/01-2017/04/30)

Ministry of Science and Technology (MOST)

- Multidisciplinary study of novel NMDA modulation for neurodegenerative disorder (1/3)
(MOST 105-2632-B-039-003-)(2016/08/01-2017/07/31)